Page Banner

United States Department of Agriculture

Agricultural Research Service

Research Project: Novel Functions and Biomarkers for Vitamins and Minerals

Location: Obesity and Metabolism Research Unit

Title: Vitamin D Supplemntation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate

Authors
item Havens, Peter -
item Hazra, Rohan -
item Stephensen, Charles
item Kiser, Jennifer -
item Flynn, Patricia -
item Wilson, Craig -
item Rutledge, Brandy -
item Bethel, James -
item Pan, Cynthia -
item Woodhouse, Leslie
item Van Loan, Marta
item Lui, Nancy -
item Lujan-Zilbermann, Jorge -
item Baker, Alyne -
item Kapogiannis, Bill -
item Gordon, Cathleen -
item Mulligan, Kathleen -

Submitted to: Antiviral Therapy
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: February 4, 2014
Publication Date: February 17, 2014
Citation: Havens, P.L., Hazra, R., Stephensen, C.B., Kiser, J., Flynn, P.M., Wilson, C.M., Rutledge, B., Bethel, J., Pan, C., Woodhouse, L.R., Van Loan, M.D., Lui, N., Lujan-Zilbermann, J., Baker, A., Kapogiannis, B.G., Gordon, C.M., Mulligan, K. 2014. Vitamin D Supplemntation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate. Antiviral Therapy. doi: 10.3851/imp2755.

Interpretive Summary: BACKGROUND: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART) containing or not containing TDF. METHODS: A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (no-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was +7.7 pg/mL in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth.

Technical Abstract: BACKGROUND: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART) containing or not containing TDF. METHODS: A randomized controlled trial in HIV+ youth ages 18-25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (no-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group. RESULTS: At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was +7.7 pg/mL in the TDF/VITD group, compared to -1.7 (no-TDF/VITD, p=0.010); -1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035). CONCLUSIONS: These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth.

Last Modified: 7/25/2014
Footer Content Back to Top of Page